Test targeted medicine with radiation for advanced skin cancer
Treatments studied
Part of Cancer clinical trials.
This Phase 2 study looks at using a medication that blocks the “Sonic Hedgehog” pathway together with radiotherapy to reduce future problems from locally advanced basal cell carcinoma (BCC). It’s for people whose cancer responded completely to the first Sonic Hedgehog pathway inhibitor treatment and where doctors can confirm that response with a tissue test.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- Your basal cell carcinoma is locally advanced and has not come back (no recurrence)
- Your first Sonic Hedgehog pathway inhibitor treatment led to a complete response confirmed by a biopsy (tissue test)
- You have scans or photos from before the Sonic Hedgehog treatment so the original tumor area can be mapped for radiation
- There is no spread to distant parts of the body (no metastasis)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study registers people in the Netherlands who have certain types of basal cell skin cancer and take an oral hedgehog-blocking medicine. It may help doctors understand how well these tablets work and how patients do in real life.
This trial tests a new drug (SP-002) combined with vismodegib for people with locally advanced basal cell carcinoma, a type of skin cancer that can't be treated with surgery or has come back after surgery. The goal is to see if this combination is safe and effective.
This study tests how well the immunotherapy medicine nivolumab works—either by itself or combined with other immune-boosting drugs—for people with advanced basal cell carcinoma that can’t be removed by surgery or has spread. It’s also looking at what to do if the cancer grows again after an earlier immunotherapy.
This trial tests if giving a combination of two immunotherapy drugs (nivolumab and relatlimab) before surgery works better than one drug alone for people with large or high-risk basal cell skin cancer that needs surgery. The goal is to shrink the cancer and make surgery easier.
This trial tests an adaptive (adjusted) dosing plan using vismodegib for people with advanced basal cell carcinoma. It may help control the cancer while balancing side effects, and your team will closely monitor how your tumors respond.
This trial tests a combination of blue-light therapy (a type of photodynamic therapy) and an oral medication called sonidegib for people with multiple basal cell carcinomas (BCCs). It may be an option if you have several BCCs that are not suitable for surgery or radiation, or if you prefer not to have surgery.
Hear when a new Basal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.